Method for generating anti-variable region monoclonal antibodies

• US 20070048306A1
• Filed: 08/30/2006
• Published: 03/01/2007
• Est. Priority Date: 08/30/2005
• Status: Abandoned Application

• Current Assignee: Centocor Incorporated (Johnson & Johnson)
• Original Assignee: Centocor Incorporated (Johnson & Johnson)
• Inventors: Giles-Komar, Jill, Rycyzyn, Michael, Staquet, Kimberly
• Application Number:
  US11/512,911
• Publication Number:
  US 20070048306A1
• Time in Patent Office: Days
• US Class Current: 424/144.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/4208 against an idiotypic determinant on Ig

Abstract

Methods for generating anti-variable region monoclonal antibodies in rodents are disclosed. The anti-variable region mAbs are useful as therapeutic agents, diagnostic agents or research reagents.

Claims

1. A method for generating anti-variable region monoclonal antibodies in a rodent comprising the steps of:

a) administering a dendritic cell maturation agent to the rodent;

b) immunizing the rodent with a target mAb;

c) isolating anti-variable region monoclonal antibodies.

3. The method of claim 1 or 2 wherein the dendritic cell maturation agent is a type I interferon, tissue necrosis factor-α

, interleukin-6, prostaglandin-E2, interleukin-1α

, interleukin-1β

, interleukin-18, interleukin-12, interleukin-4, interleukin-23, interferon-γ

, granulocyte-macrophage colony-stimulating factor or dendritic cell associated maturation factor agonist monoclonal antibody.

4. The method of claim 3 wherein the dendritic cell maturation agent is adminstered singly or in combination with another dendritic cell maturation agent.

5. The method of claim 3 wherein the type I interferon is at least one of interferon-α

(IFN-α

), interferon-β

(IFN-β

), IFN-δ

, IFN-α

1, IFN-α

2, IFN-α

2a, IFN-α

2b, IFN-α

4, IFN-α

II1, IFN-α

Con1, IFN-α

LE, IFN-α

Ly or IFN-β

2.

6. The method of claim 5 wherein the type I interferon is a combination of IFN-α

and IFN-β

.

11. The method of claim 1 or 2 wherein the rodent is a mouse.

12. The method of claim 11 wherein the mouse is a BALB/c mouse.

13. The method of claim 1 or 2 wherein the rodent is a rat.

2. A method for generating anti-variable region monoclonal antibodies in a rodent comprising the steps of:

a) administering a dendritic cell maturation agent to the rodent;

b) immunizing the rodent with a target mAb;

c) administering a B cell expansion agent to the rodent;

d) isolating anti-variable region monoclonal antibodies.

7. The method of claim 2 wherein the B cell expansion agent is at least one of CD40 agonist, CD154, C3a, C3b, anti-IgM, BAFF, anti-CD80, or anti-CD86.

8. The method of claim 7 wherein the B cell expansion agent is a CD40 agonist.

9. The method of claim 8 wherein the CD40 agonist is an anti-CD40 antibody.

10. The method of claim 9 wherein the anti-CD40 antibody is administered in an amount of about 50 μ

g to about 100 μ

g per dose.